Diagnosis & Your Test Results: The Path to Confirmation
At a Glance
Acromegaly diagnosis requires a three-step process: an IGF-1 blood test, an oral glucose tolerance test (OGTT) to measure your growth hormone (GH) nadir, and a pituitary MRI. These tests confirm if a tumor is producing excess hormone and determine its exact size and location.
Confirming a diagnosis of acromegaly involves more than just a single blood test. Because your hormones naturally fluctuate throughout the day, doctors use “dynamic” testing to see how your body responds to specific triggers [1]. This process usually follows a three-step path: screening, confirmation, and imaging.
Step 1: The IGF-1 Screening
The first step is measuring Insulin-like Growth Factor 1 (IGF-1) [1]. Unlike Growth Hormone (GH), which pulses up and down, IGF-1 levels stay relatively stable in your blood, making it the most reliable “snapshot” of your average hormone activity [2].
- Age and Sex Matter: Your “normal” IGF-1 level depends heavily on how old you are and your sex [1]. A level that is healthy for a teenager would be dangerously high for a 50-year-old. When you look at your lab report, ensure your result is being compared to the reference range for your specific age group [1].
- Interferences: Conditions like liver disease, kidney failure, or poorly controlled diabetes can sometimes cause a “false low” IGF-1, even if acromegaly is active [2][3].
Step 2: The Sugar Water Test (OGTT)
To confirm the diagnosis, doctors use the Oral Glucose Tolerance Test (OGTT), often called the “gold standard” [4]. During this test, you will drink a standardized, highly concentrated glucose (sugar) drink. The medical team will then draw your blood multiple times over a period of about two hours to see how your hormones react. In a healthy body, drinking a high-sugar solution causes the pituitary gland to stop making Growth Hormone [4]. In acromegaly, the tumor ignores the sugar and continues to pump out GH [1].
- The GH Nadir: This is the lowest level your Growth Hormone reaches during the test.
- The Threshold: Using modern, highly sensitive tests, a GH nadir of less than 0.4 µg/L is generally considered a normal result that “rules out” active acromegaly [4][5]. If your GH stays above this level, it confirms the tumor is producing hormone autonomously [1].
Step 3: Pituitary MRI & The Knosp Grade
Once the blood tests confirm the hormone excess, a gadolinium-enhanced MRI is used to find the tumor [6]. Gadolinium is a contrast dye that helps the tumor stand out from the normal pituitary gland [7].
Tumor Size
Your report will likely classify the tumor based on its size:
- Microadenoma: Less than 10 millimeters (mm) [6].
- Macroadenoma: 10 millimeters or larger [6]. Macroadenomas are more common in acromegaly and may require more complex treatment if they press on nearby structures like the optic nerves [8].
Understanding the Knosp Grade
The Knosp scale is a grading system (0 to 4) that tells your surgeon how far the tumor has spread sideways into a nearby area called the cavernous sinus [9].
- Grades 0, 1, and 2: These are considered “non-invasive.” The tumor is contained or only slightly touching nearby structures. These usually have higher rates of successful surgical removal [10][9].
- Grades 3 and 4: These indicate the tumor has “invaded” or wrapped around the internal carotid artery [9]. While still treatable, these higher grades are more challenging for surgeons to remove completely [11][12].
Knowing these specific terms—GH nadir, macroadenoma, and Knosp grade—will help you have a much more detailed conversation with your endocrinologist and surgeon about your treatment plan.
Read next: Standard of Care Treatment: Surgery & Medical Therapies
Common questions in this guide
What is the first test used to diagnose acromegaly?
Why do I need to take the sugar water test (OGTT)?
What does GH nadir mean on my lab report?
What is a Knosp grade on an MRI report?
Can other conditions affect my IGF-1 test results?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Related questions
Get notified when new evidence is published on Acromegaly.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Was my IGF-1 result compared against a reference range adjusted specifically for my age and sex?
- 2.What was my exact GH nadir (lowest point) during the sugar water test? Was it below 0.4 µg/L?
- 3.Does my MRI report mention a Knosp grade, and what does that mean for the success rate of my surgery?
- 4.Is my tumor a microadenoma or a macroadenoma, and is it touching or pressing on my optic nerves?
- 5.Are there any conditions I have, like diabetes or liver issues, that might have made my IGF-1 result lower than it actually is?
References
References (12)
- 1
Biochemical following-up of treated acromegaly. Limitations of the current determinations of IGF-I and perspective.
Granada ML
Minerva endocrinologica 2019; (44(2)):143-158 doi:10.23736/S0391-1977.18.02922-X.
PMID: 30311754 - 2
Acromegaly presenting with low insulin-like growth factor-1 levels and diabetes: a case report.
Wijayaratne DR, Arambewela MH, Dalugama C, et al.
Journal of medical case reports 2015; (9()):241 doi:10.1186/s13256-015-0736-z.
PMID: 26514337 - 3
Acromegaly presenting with normal insulin-like growth factor-1 levels in a patient with advanced liver cirrhosis.
Kilcoyne C, Burke K, O'Reilly MW, et al.
BMJ case reports 2026; (19(2)) doi:10.1136/bcr-2025-266505.
PMID: 41713883 - 4
Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?
Dobri G, Niwattisaiwong S, Bena JF, et al.
Endocrine 2019; (64(1)):139-146 doi:10.1007/s12020-018-1805-z.
PMID: 30415402 - 5
Value of Early Post-Operative Growth Hormone Testing in Predicting Long-Term Remission and Residual Disease after Transsphenoidal Surgery for Acromegaly.
Wang YY, Waqar M, Abou-Zeid A, et al.
Neuroendocrinology 2022; (112(4)):345-357 doi:10.1159/000517476.
PMID: 34052822 - 6
Diagnosis and Treatment of Acromegaly: An Update.
Ershadinia N, Tritos NA
Mayo Clinic proceedings 2022; (97(2)):333-346 doi:10.1016/j.mayocp.2021.11.007.
PMID: 35120696 - 7
Rethinking MRI Protocols for Pituitary Microadenomas: Prioritizing Non-Contrast Imaging for Safe Follow-Up.
Zarei F, Nematollahi F, Jalil A, et al.
Tomography (Ann Arbor, Mich.) 2025; (11(9)) doi:10.3390/tomography11090105.
PMID: 41003488 - 8
Adenoma size and postoperative IGF-1 levels predict surgical outcomes in acromegaly patients: results of the Swiss Pituitary Registry (SwissPit).
Kempf J, Schmitz A, Meier A, et al.
Swiss medical weekly 2018; (148()):w14653.
PMID: 30141524 - 9
Predicting early post-operative remission in pituitary adenomas: evaluation of the modified knosp classification.
Buchy M, Lapras V, Rabilloud M, et al.
Pituitary 2019; (22(5)):467-475 doi:10.1007/s11102-019-00976-6.
PMID: 31286328 - 10
Efficacy of transsphenoidal surgery in achieving biochemical cure of growth hormone-secreting pituitary adenomas among patients with cavernous sinus invasion: a systematic review and meta-analysis.
Briceno V, Zaidi HA, Doucette JA, et al.
Neurological research 2017; (39(5)):387-398 doi:10.1080/01616412.2017.1296653.
PMID: 28301972 - 11
Machine learning in predicting early remission in patients after surgical treatment of acromegaly: a multicenter study.
Qiao N, Shen M, He W, et al.
Pituitary 2021; (24(1)):53-61 doi:10.1007/s11102-020-01086-4.
PMID: 33025547 - 12
Experience of Endoscopic Endonasal Approach for 803 Pituitary Tumors With Cavernous Sinus Invasion.
Zhu H, Li C, Gui S, et al.
The Journal of craniofacial surgery 2022; (33(2)):e118-e122 doi:10.1097/SCS.0000000000008049.
PMID: 34334752
This page explains acromegaly diagnostic testing and terminology for educational purposes. Always consult your endocrinologist and neurosurgeon to interpret your specific lab results and MRI reports.